Sjogren's Syndrome Market Outlook 2034 - Clinical Trials, Market Size, Medication, Prevalence, and Key Companies by DelveInsight

Prominent Sjogren's syndrome companies include Rise Therapeutics, Bristol-Myers Squibb, Resolve Therapeutics, Novartis, Horizon Therapeutics, Dompe Farmaceutici, Horizon Therapeutics (Amgen), Sylentis, OSE Immunotherapeutics, Servier, Johnson & Johnson, and several others.

Sjogren's Syndrome Market Summary
In 2023, the Sjogren's syndrome market size across the seven major markets (7MM) was valued at approximately USD 1.9 billion and is expected to witness steady growth through 2034.

Sjogren's syndrome is an autoimmune disease that primarily disrupts the salivary and lacrimal glands, causing hallmark symptoms like dry eyes and dry mouth. The condition is classified into primary Sjogren's syndrome (occurring independently) and secondary Sjogren's syndrome (developing alongside other autoimmune disorders such as rheumatoid arthritis and lupus). Beyond glandular manifestations, the disorder may impact multiple organs, resulting in joint pain, skin rashes, and systemic complications.

Diagnosis typically includes clinical evaluation, ocular and oral tests, blood analyses, and salivary gland biopsies or ultrasounds. Around 3 million cases were diagnosed across the 7MM in 2023, with numbers anticipated to rise over time. Although there is currently no curative therapy, treatment primarily focuses on symptom management, using artificial tears, saliva substitutes, secretagogues, and immunosuppressants for severe systemic involvement.
Emerging therapies such as lanalumab, CFZ533 (iscalimab), and VIB4920 (dazodalibep) hold strong potential to transform the treatment landscape. The United States remains the largest market, accounting for approximately 62% of total share in 2023. Despite therapeutic advancements, unmet needs persist for more effective therapies and reliable biomarkers. A notable milestone occurred in November 2024, when the FDA granted Breakthrough Therapy Designation to nipocalimab for moderate-to-severe Sjogren's disease, marking progress in novel treatment options.

To learn more about the Sjogren's syndrome market outlook, drug uptake, treatment landscape, and epidemiological trends, visit: Sjogren's syndrome Market Insights - https://www.delveinsight.com/report-store/sjogrens-syndrome-market-size?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

DelveInsight's Comprehensive Market Report
DelveInsight's report, "Sjogren's Syndrome Market Insights, Epidemiology, and Market Forecast-2034," provides a detailed examination of disease epidemiology, market trends, and forecast data across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
The market is expected to grow considerably due to rising disease prevalence, heightened awareness, and the launch of several pipeline therapies currently in different clinical stages. The report outlines existing treatments, emerging drug candidates, market share distribution, and forecasted market dynamics (2020-2034). It also includes an analysis of treatment algorithms, key drivers and restraints, and unmet medical needs, helping stakeholders pinpoint opportunities and assess market potential.

Key Highlights from the Sjogren's Syndrome Market Report
• In 2023, the Sjogren's syndrome market size stood at approximately USD 1.9 billion, with continued growth projected through 2034 across the 7MM.
• Novartis and Amgen are expected to be major contributors, with their drugs CFZ533 (iscalimab) and VIB4920 (dazodalibep) forecasted to generate leading revenues by 2034.
• Around 1.5 million diagnosed cases were reported in 2023 across the 7MM, a number anticipated to increase during 2024-2034.
• In the U.S., most antigen-specific cases were linked to anti-Ro/SSA and anti-La/SSB antibodies.
• The U.S. had the largest treated patient population, while Japan recorded the fewest (~54,000 treated cases) in 2023; both figures are projected to rise by 2034.
• Within EU4 and the UK, the disease predominantly affects females, with the UK showing the highest gender-specific prevalence in 2023.
• Key companies developing therapies include Rise Therapeutics, Bristol-Myers Squibb, Resolve Therapeutics, Novartis, Horizon Therapeutics, Dompe Farmaceutici, Amgen, Sylentis, OSE Immunotherapeutics, Servier, and Johnson & Johnson.
• Multiple pipeline therapies (R-2487, BMS-986325, RSLV-132, CFZ533, VIB4920, VAY736, Dazodalibep, OXERVATE, Tivanisiran, Lusvertikimab, Nipocalimab, and others) are in clinical trials and expected to reshape the market.
• In March 2025, Johnson & Johnson received Fast Track Designation for nipocalimab, following its Breakthrough Therapy Designation in November 2024, highlighting its leadership in advanced Sjogren's research.
• In June 2024, J&J's Phase II DAHLIAS study demonstrated significant improvement in disease activity with nipocalimab, further validating its therapeutic potential.

For more information on regional treatment pathways, request a sample at: Sjogren's Syndrome Treatment Market - https://www.delveinsight.com/sample-request/sjogrens-syndrome-market-size?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Sjogren's Syndrome Overview
Sjogren's syndrome (SS) is a chronic autoimmune condition marked by lymphocytic infiltration and dysfunction of exocrine glands, primarily targeting salivary and lacrimal glands. This results in dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia)-together termed sicca syndrome.
The disease exists in two forms: primary SS (pSS), occurring alone, and secondary SS (sSS), associated with other autoimmune diseases such as rheumatoid arthritis or systemic lupus erythematosus.

Beyond glandular effects, systemic manifestations can involve musculoskeletal, renal, pulmonary, neurological, and dermatologic systems.
Diagnosis relies on clinical evaluation, autoantibody testing, ocular and oral examinations, and minor salivary gland biopsies.

Although no curative therapy exists, management remains symptomatic, utilizing secretagogues, artificial tears, saliva substitutes, and immunomodulators.

Research into targeted biologics and small molecules is advancing rapidly, aiming to modify disease progression. The growing global prevalence continues to drive demand for improved diagnostics and therapeutics.

Sjogren's Syndrome Epidemiology Insights
In 2023, the U.S. reported about 1.5 million diagnosed cases, expected to grow steadily through 2034. Most cases showed autoantibody positivity (anti-Ro/SSA and anti-La/SSB).

DelveInsight segments the epidemiology (2020-2034) into:
• Total prevalence
• Severity-based prevalence
• Gender-specific prevalence
• Diagnosed episodic vs. chronic cases

Download the full epidemiology breakdown at: Sjogren's Syndrome Epidemiological Insights - https://www.delveinsight.com/report-store/sjogrens-syndrome-market-size?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Sjogren's Syndrome Market Outlook
Current U.S. treatment options include local, systemic, and biologic therapies:
• Local: Pilocarpine, cevimeline, topical fluoride, topical cyclosporine, autologous serum eye drops
• Systemic: Corticosteroids, hydroxychloroquine, immunosuppressants, and DMARDs (methotrexate, cyclosporine A, azathioprine, leflunomide, mycophenolic acid)
• Biologics: Rituximab (widely used), TNF-α inhibitors, and BAFF-targeting agents in development

Despite availability, managing SS remains challenging due to symptom diversity and comorbidities, emphasizing the need for disease-specific biomarkers.
Emerging mid-stage clinical candidates like RSLV-132, VAY736, CFZ533, OXERVATE, VIB4920, and SOTYKTU are anticipated to revolutionize care by 2030.

Market growth is fueled by rising prevalence, early diagnosis, advances in immunology, and government investment. However, challenges such as lack of curative therapy, delayed diagnosis, high biologic costs, and limited reimbursement persist.

Still, biotech innovations and pharma-research collaborations are expected to address these issues and drive sustained growth.

Sjogren's Syndrome Drugs, Pipeline, and Key Companies
Sjogren's Syndrome Marketed Drugs:
• SALAGEN (pilocarpine) - ADVANZ Pharma
• EVOXAC (cevimeline) - Daiichi Sankyo
• CFZ533 (iscalimab) - Novartis
• VIB4920 (dazodalibep) - Amgen
• SOTYKTU (deucravacitinib) - Bristol Myers Squibb
• VAY736 (ianalumab) - Novartis
• OXERVATE (cenegermin) - Dompe Farmaceutici

For full therapy insights, visit: Sjogren's Syndrome Medications and Companies - https://www.delveinsight.com/sample-request/sjogrens-syndrome-market-size?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Report
• Study Period: 2020-2034
• Regions Covered: 7MM (US, EU5, Japan)
• Key Companies: Rise Therapeutics, Bristol-Myers Squibb, Resolve Therapeutics, Novartis, Amgen, Dompé Farmaceutici, Sylentis, OSE Immunotherapeutics, Servier, Johnson & Johnson, and others
• Therapeutic Assessment: Current and emerging therapies
• Market Dynamics: Drivers, barriers, competitive analysis (SWOT, PESTLE, Porter's Five Forces, BCG Matrix)
• Key Insights: Unmet needs, KOL views, reimbursement analysis

Explore the pipeline in detail: Sjogren's Syndrome Clinical Trials and Pipeline Analysis - https://www.delveinsight.com/sample-request/sjogrens-syndrome-market-size?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.